Scientists in Germany claim to have made a breakthrough with a nasal vaccine that can stop Covid-19 from taking hold in the body. The vaccine is made from a live but weakened form of the coronavirus and has shown promising results in hamster studies, achieving "sterilizing immunity" and preventing illness.
The vaccine works by boosting mucosal immunity, which is the defense system in the upper airways where the virus first enters the body. This approach is different from traditional vaccines that target the bloodstream, and it may be more effective against new variants of the virus.
In hamster studies, two doses of the nasal vaccine created a stronger immune response than an mRNA-based vaccine or one that uses an adenovirus to ferry instructions into cells. The researchers believe this is because the live weakened vaccine closely mimics the natural process of infection and can target multiple parts of the virus.
While the results are encouraging, experts caution that more tests need to be done before the vaccine is ready for human use. The current vaccines in use in China and India rely on harmless adenoviruses to ferry instructions into cells, but their effectiveness data has not been published.
There are several other nasal vaccines in development, including one from Mount Sinai and another from Codagenix, which uses a live but weakened version of the virus. These studies may provide valuable insights into the effectiveness of this approach and could potentially lead to more effective Covid-19 vaccines.
However, some experts also point out that respiratory infections can be tough targets for inhaled vaccines, such as FluMist, which has shown limited effectiveness against adults. Nonetheless, live attenuated viruses have proven potent in other vaccine applications, so it's a promising approach.
It's worth noting that even if these nasal vaccines show promise, they may not be suitable for everyone, particularly those with compromised immunity. The researchers are eager to start phase I clinical trials to test the vaccine in humans and determine its safety and efficacy.
The vaccine works by boosting mucosal immunity, which is the defense system in the upper airways where the virus first enters the body. This approach is different from traditional vaccines that target the bloodstream, and it may be more effective against new variants of the virus.
In hamster studies, two doses of the nasal vaccine created a stronger immune response than an mRNA-based vaccine or one that uses an adenovirus to ferry instructions into cells. The researchers believe this is because the live weakened vaccine closely mimics the natural process of infection and can target multiple parts of the virus.
While the results are encouraging, experts caution that more tests need to be done before the vaccine is ready for human use. The current vaccines in use in China and India rely on harmless adenoviruses to ferry instructions into cells, but their effectiveness data has not been published.
There are several other nasal vaccines in development, including one from Mount Sinai and another from Codagenix, which uses a live but weakened version of the virus. These studies may provide valuable insights into the effectiveness of this approach and could potentially lead to more effective Covid-19 vaccines.
However, some experts also point out that respiratory infections can be tough targets for inhaled vaccines, such as FluMist, which has shown limited effectiveness against adults. Nonetheless, live attenuated viruses have proven potent in other vaccine applications, so it's a promising approach.
It's worth noting that even if these nasal vaccines show promise, they may not be suitable for everyone, particularly those with compromised immunity. The researchers are eager to start phase I clinical trials to test the vaccine in humans and determine its safety and efficacy.